US · OSUR
OraSure Technologies, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Bethlehem, PA 18015
- Website
- orasure.com
Price · as of 2025-12-31
$2.95
Market cap 230.38M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $35.35 | +1,098.31% |
| Intrinsic Value(DCF) | $1.18 | -60% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $26.57 | +800.71% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $9.48 | $61.40 | $0.60 | $0.67 | $0.00 |
| 2012 | $5.98 | $87.99 | $0.98 | $1.35 | $0.00 |
| 2013 | $8.48 | $28.65 | $0.84 | $1.47 | $0.00 |
| 2014 | $7.35 | $30.63 | $1.17 | $2.04 | $0.00 |
| 2015 | $6.93 | $32.01 | $1.46 | $3.23 | $2.90 |
| 2016 | $11.46 | $32.35 | $1.80 | $4.78 | $3.77 |
| 2017 | $18.25 | $43.86 | $40.01 | $6.65 | $22.31 |
| 2018 | $11.01 | $35.74 | $22.14 | $6.00 | $5.52 |
| 2019 | $5.92 | $35.90 | $1.86 | $5.74 | $0.00 |
| 2020 | $11.27 | $35.06 | $2.31 | $4.20 | $0.00 |
| 2021 | $6.81 | $160.04 | $0.55 | $3.13 | $0.00 |
| 2022 | $6.10 | $33.49 | $162.80 | $3.36 | $0.00 |
| 2023 | $7.23 | $110.32 | $184.01 | $9.04 | $9.17 |
| 2024 | $3.49 | $36.58 | $2.44 | $3.66 | $11.45 |
| 2025 | $2.96 | $35.35 | $0.00 | $0.00 | $26.57 |
AI valuation
Our deep-learning model estimates OraSure Technologies, Inc.'s (OSUR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $35.35
- Current price
- $2.95
- AI upside
- +1,098.31%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.18
-60% upside
Graham-Dodd
—
— upside
Graham Formula
$26.57
+800.71% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OSUR | OraSure Technologies, Inc… | $2.95 | 230.38M | +1,098% | -60% | — | +801% | -3164.74 | 0.64 | 1.89 | -3.83 | -1210.05 | 0.64 | 41.90% | -59.23% | -59.76% | -0.02% | -27.37% | -0.02% | 0.00 | — | 6.58 | 0.01 | 0.00 | 26154.00% | -3810.00% | -10023.00% | -0.02% | 0.00 | -0.02% | 0.00% | 0.00% | 6.91% | -3.19 | -4083.36 | 1.89 | 2.48 |
| GNFT | Genfit S.A. | $10.00 | 497.97M | +550% | -76% | -82% | -52% | 103.96 | 2.26 | 2.34 | 16.42 | — | 7.38 | 99.55% | 4.90% | 2.25% | 2.20% | 4.87% | 0.93% | 0.90 | 0.69 | 1.23 | 1.19 | -2.36 | -10517.00% | 13456.00% | -12455.00% | 9.08% | 0.20 | 25.88% | 0.00% | 0.00% | 7.69% | 41.76 | 9.63 | 2.04 | -1.81 |
| NAUT | Nautilus Biotechnology, I… | $2.42 | 305.66M | — | — | — | — | -4.96 | 1.87 | — | -4.18 | — | 1.87 | 0.00% | — | — | -32.27% | -69.30% | -27.20% | 0.19 | — | 13.33 | 13.00 | -0.34 | -1607.00% | — | -1517.00% | -17.74% | -6.38 | -53.89% | 0.00% | 0.00% | 0.05% | -3.28 | -4.22 | — | 2.18 |
| NTHI | Neonc Technologies Holdin… | $10.22 | 198.27M | — | — | — | — | — | — | — | — | — | — | 100.00% | -8605.45% | -14335.50% | 122.08% | 110.23% | -508.20% | 0.00 | -2.64 | 0.25 | 0.02 | 0.00 | -2125.00% | 1779.00% | 12414.00% | — | -0.47 | 65.03% | — | 0.00% | — | — | — | — | — |
| NYXH | Nyxoah S.A. | $4.08 | 152.37M | +571% | +9% | — | — | -4.96 | 2.47 | 61.97 | -3.74 | -29.59 | 4.46 | 65.67% | -1300.80% | -1310.24% | -53.42% | -113.83% | -39.94% | 0.20 | -30.90 | 4.56 | 4.13 | 0.20 | 1677.00% | 398.00% | -79.00% | -19.74% | -2.29 | -107.03% | 0.00% | 0.00% | 0.94% | -3.69 | -3.93 | 48.05 | 1.18 |
| PRE | Prenetics Global Limited | $16.91 | 237.65M | +204% | +11,114% | — | — | -4.22 | 1.27 | 2.41 | -4.86 | -30.15 | 1.71 | 52.98% | -40.46% | -63.13% | -30.55% | -32.70% | -25.27% | 0.01 | -155.12 | 3.01 | 2.33 | 0.89 | 1401.00% | 20172.00% | -2645.00% | -9.89% | -0.79 | -19.26% | 0.00% | 0.00% | 0.00% | -4.37 | -7.42 | 1.77 | 4.78 |
| PROF | Profound Medical Corp. | $7.61 | 229.84M | +279% | -61% | — | — | -6.11 | 2.81 | 16.71 | -4.69 | — | 2.82 | 65.89% | -309.57% | -260.45% | -60.70% | -267.75% | -48.72% | 0.08 | — | 10.52 | 9.44 | 1.95 | -2074.00% | 4123.00% | 373.00% | -13.80% | -3.57 | -199.52% | 0.00% | 0.00% | 18.51% | -3.82 | -5.12 | 11.81 | 5.24 |
| STIM | Neuronetics, Inc. | $1.34 | 91.77M | +1,696% | +34,643% | — | — | -3.68 | 5.81 | 2.15 | -6.51 | -11.71 | -15.27 | 72.32% | -46.15% | -58.36% | -141.29% | -54.52% | -34.06% | 2.98 | -4.74 | 1.86 | 1.41 | -1.84 | 3143.00% | 496.00% | -565.00% | -20.18% | -0.99 | -51.22% | 0.00% | 0.00% | 0.00% | -6.48 | -6.90 | 2.99 | -3.34 |
| TARA | Protara Therapeutics, Inc… | $6.36 | 245.43M | — | — | — | — | -1.86 | 0.50 | — | 1.70 | — | 0.51 | 0.00% | — | — | -37.88% | -1031.24% | -34.25% | 0.03 | — | 15.71 | 15.54 | 3.24 | -3922.00% | — | -460.00% | -43.33% | -3.27 | -752.56% | 0.00% | 0.00% | 150.03% | 1.69 | 2.31 | — | 1.75 |
| UTMD | Utah Medical Products, In… | $66.61 | 213.4M | +632% | -36% | -27% | -87% | 19.68 | 1.86 | 5.77 | 7.99 | — | 2.13 | 51.60% | 29.60% | 29.30% | 9.54% | 26.71% | 9.21% | 0.00 | — | 37.62 | 34.36 | -5.03 | -1212.00% | -583.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 1.38% | 11.96 | — | 3.54 | 42.25 |
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
- CEO
- Carrie Eglinton Manner
- Employees
- 501
- Beta
- 0.91
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.18 ÷ $2.95) − 1 = -60% (DCF, example).